Ambrisentan: new drug. Too risky in mildly symptomatic pulmonary hypertension.

  • Published 2009 in Prescrire international

Abstract

(1) In patients with mildly symptomatic pulmonary hypertension (stage III), there is no firm evidence that ambrisentan reduces mortality or slows disease progression. In contrast, ambrisentan has frequent and sometimes serious adverse effects; (2) In patients whose physical activity is markedly restricted by pulmonary hypertension, it is better to continue… (More)

Topics

Cite this paper

@article{2009AmbrisentanND, title={Ambrisentan: new drug. Too risky in mildly symptomatic pulmonary hypertension.}, author={}, journal={Prescrire international}, year={2009}, volume={18 100}, pages={54} }